{"id":6012,"date":"2020-12-16T08:07:07","date_gmt":"2020-12-16T08:07:07","guid":{"rendered":"https:\/\/www.springboard.pro\/?p=2115"},"modified":"2026-09-03T14:22:43","modified_gmt":"2026-09-03T14:22:43","slug":"drug-delivery-trends-for-2021","status":"publish","type":"blog","link":"https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-trends-for-2021\/","title":{"rendered":"Drug Delivery Trends for 2021"},"content":{"rendered":"\n
\n
\n
\n
\n

Drug delivery devices are evolving rapidly, and Sanner is in the privileged position of being at the center of developing many of them.<\/p>\n

Based on our experience, here are our top 5 trends to watch for 2021:<\/p>\n

1. The COVID dividend<\/strong><\/p>\n

Amongst all of the disruption, confinement, and loss caused by COVID-19, there are some unexpected positive effects on human life.<\/p>\n

The business case for vaccine development has been difficult before COVID: it takes years of development with all the failure risk common to drug development, and the financial return can be limited because each patient might receive one or two doses for their entire life, or at most once per year.\u00a0 Compare that to chronic diseases like diabetes where each patient receives multiple doses per day.\u00a0 However, many governments have now realized that vaccines are necessary for economic security if nothing else.\u00a0 They have accepted that they must invest in vaccines at risk, and sometimes in advance, to ensure that research, development, and supply are possible.\u00a0 It seems inconceivable that governments and philanthropic funds will stop vaccine funding in the near future.<\/p>\n

 <\/p>\n

Wider than vaccines, we should expect to see strong investment from both public and private funds in autoimmune drugs (the only drugs currently known to help treat COVID-19), diagnostics, critical care infrastructure, and Personal Protective Equipment.<\/p>\n

2. Reduced environmental impact<\/strong><\/p>\n

The pharmaceutical and medical device industries have long prioritized safety, efficacy, regulatory compliance, usability and economics when developing drugs and devices.\u00a0 We have seen a marked increase in the importance placed on reducing environmental impact in new device developments.\u00a0 Part of this is driven by corporate environmental goals.<\/p>\n

Springboard has worked on multiple projects to reduce environmental impact, for example:<\/p>\n